Overexpression of EGFR has been identified in many cancers from epithelial origins, including HNSCC, where overexpression of EGFR is found in over 95% of all tumors [25,26] and has been associated with a more aggressive malignant phenotype, including increased resistance to treatment and poorer clinical outcome. This evidence concerns the gene EGFR and cancer.